Momenta Pharmaceuticals, Inc. (MNTA)

[biotech2020]

From fiercepharma.com, http://www.fiercepharma.com/pharma/teva-at-court-s-mercy-key-copaxone-patent-trial-analysts?utm_medium=nl&utm_source=internal&mrkid=4640400&mkt_tok=eyJpIjoiT1RneVlXUTFaVFUyT0dabSIsInQiOiJkdkJLY0UydTU1TFpNRmozbFdac2UwOWRFMDZxeFRJTjRockI1Rk5MTHZqQU9QdjF3V083alRmN2Q5eHZCdlwvck9vaktZUEllMnF2NVwvSmROeXNMaTFhN0txeFBFeDgwMFBqTHFFeVdiRUhJPSJ9
It’s Day 2 of the 7-day district court hearing into patent protection on Teva’s newer version of multiple sclerosis blockbuster Copaxone, and at this point, things aren’t looking great for the Israeli drugmaker.
So far, trial proceedings “provide little reason to believe that [the] district court may produce a different decision” from the inter partes review process at the U.S. Patent and Trademark Office’s Patent Trial and Appeals Board. That board recently nixed three 2030 patents on Teva's 40-mg formulation of its big-earning MS drug.